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1. Introduction 
Present in all animal species, even if less developed in the lowest classes of the animal 
kingdom, the liver fulfils many vital functions of the utmost importance for the organism’s 
survival. In adult humans, the biological significance of liver is attested by its anatomical 
localisation, its volume, its complexity, and by the density of the cellular elements it is 
composed of. Located in the right upper quadrant of the abdominal cavity, just below the 
diaphragm (Fig. 1), the liver represents, as a matter of fact, the largest visceral organ in the 
human body (about 2.5% of the dry body weight of an adult), and its parenchyma is 
constituted of more than 300 billion cells (Conti, 2005). 
Physiological investigations have assigned to the liver a complex array of more than 500 
different functions, the majority of which still remain unknown in their molecular mechanisms 
and controls. These functions include a number of key metabolic and regulatory activities, as 
well as processes crucial to the organism’s defence (Arias et al., 2009). The principal hepatic 
functions are schematised in Fig. 2. Indeed, besides carrying a central role in the metabolism of 
carbohydrates, lipids and proteins, the liver regulates other critical homeostatic functions, such 
as endocrine activity and haemostasis (synthesis/activation/catabolism of hormonal 
compounds, and of the majority of coagulation’s/fibrinolysis’ factors and inhibitors), and it 
directly acts as an integrant part of the systemic reaction to injury by, for example, modulating 
the immune response and synthesizing proteins from the “acute phase” (Nahmias et al., 2006). 
In addition to its multiple metabolic activities, the liver also represents the first line of defence 
of the whole organism against exogenous or toxic substances. The liver is, in effect, the major 
site for inactivation of toxins and xenobiotics, favours their removal from the blood and 
further elimination from the organism through bile secretion (processes of biotransformation 
and excretion) 1 (Arias et al., 2009). 
                                                                 
1 Biotransformation of drugs, xenobiotics, toxins and endogenous compounds.  
Part of lipophilic compounds can accumulate in the body (mainly in fat and bone tissues) or, 
alternatively, they need to be transformed in hydrophilic substances, in order to be more readily 
eliminated (excreted). Most of drugs are poorly hydrosoluble, and are metabolised (biotransformed) 
mainly at the hepatic level. Biotransformation process is the principal factor that can affect the overall 
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The importance of this organ and the impossibility to substitute artificially its multiple 
activities, justify, therefore, the serious clinical consequences of its dysfunction: until now, in 
industrialized countries, liver failure (acute and chronic) is among the top ten most frequent 
causes of death (Popovic & Kozak, 1998). A fundamental and typical feature of liver lies in 
the species-specificity of its functional characteristics and susceptibility to injury, elements 
that, both, make animal models commonly used for patho-physiological and pharmaco-
toxicological studies, inadequate and poorly informative (or predictive) for humans 
(Rangarajan et al., 2004; Sivaraman et al., 2005). Examples are adverse drug reactions that 
occur in humans, which, being specifically based on liver metabolism or on hepatocellular 
sensitivity, are unpredictable or poorly understood (Park et al., 2005). 
To date, notwithstanding the long time period required (more than ten years), and the high 
financial investment necessary for the development of any new drug (estimated at around 
one billion Euros per molecule, of which, at least, one-fifth is used exclusively for 
toxicological investigations on hepatic function), almost two-thirds of the compounds that 
reach the phase III of clinical trials, demonstrate significant hepatotoxic effects in humans, 
which prevent their approval. Moreover, it is noteworthy that the hepatic toxicity (including 
idiosyncratic and chronic toxicity) unpredicted by the current experimental protocols 
represents more than one third of all the causes responsible for the withdrawal from the 
market of already approved drugs (O’Brien et al., 2004; Whitebread et al., 2005). Lastly, drug-
induced hepatotoxicity is a major clinical pitfall, accounting for 50% of all cases of acute liver 
failure. From the above considerations, it is, therefore, clear how liver plays a unique and 
central role in toxicological studies: first, because it is critical in the pharmacokinetics of 
chemicals, due to its functions of biotransformation and excretion of substances, and, second, 
since it represent a foremost target of organ-specific adverse effects of drugs and xenobiotics. 
In order to lessen and offset hepatotoxic effects, a large number of methods were developed 
and are currently applied in risk assessment procedures (in vitro and in vivo methods, human 
clinical trials, clinical case reports, etc.), or in toxicological/epidemiological studies 
(observation of the exposure-induced effects on human health), aimed to identify potential 
human hazards. Some of these methods are presented in Table 1, focusing on their features in 
relation to the fundamental characteristics required to fulfil the process of risk assessment. 
                                                                                                                                                                   
therapeutic and toxic profile of a drug; it can lead to detoxification, excretion, or, less frequently, to 
bioactivation of the chemical compound, being, thus, responsible for its biological activity, 
pharmacokinetics and clearance (Brandon et al., 2003). Biotransformation occurs in three different 
phases: metabolic phases I and II, and transport phase III. The phase I reactions (functionalization step) 
include oxidation, reduction, or hydrolysis enzymatic reactions, that are, mainly, catalysed by the 
cytochrome P450 (CYP)-depending and flavin monooxygenase superfamily enzymes. Part of these 
phase I metabolites can be eliminated by biliary excretion, whereas another part can be metabolised by 
the phase II reactions, which allow to conjugate polar compounds (and metabolites) to water-soluble 
groups (glucuronic acid, sulphate, acetate, glycine, glutathione or methyl and acetyl groups), that 
render the derivatives much more soluble. Hydrophilic derivatives can then be excreted (mainly by 
kidney, even if liver excretion through bile also takes place). The third phase of compound 
biotransformation involves active membrane transporters, which, in hepatocytes, are located at their 
two polar surface domains. Apical and canalicular ATP-binding cassette (ABC) family of drug 
transporters are responsible for xenobiotic clearance (or bile secretion); basolateral solute carrier 
transporters, such as, for example, organic anion transporters (OATs), organic cation transporters 
(OCTs), and organic anion-transporting polypeptides (OATPs), are involved in the uptake of compound 
from the blood (Pauli-Magnus & Meier, 2003; Omiecinski et al., 2010). 
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Fig. 1. Schematic view of the liver: location, macroscopical and microscopical organisation. 
Since each model possesses advantages (and limits), the most promising strategy to assess 
the toxicological risk of substances and drugs, should be, at present, a combination of all the 
information obtained from these various models (integrated testing strategy). Table 2 lists 
the principal models currently used for hepatotoxicity studies. 
Nevertheless, the predictive value for humans of current pre-clinical safety assessment 
systems is still limited and largely insufficient for a correct estimation of clinically relevant 
drug-drug interactions (DDIs) and pharmacodynamics/toxicological properties of 
compounds (ADMET profile) (Soars et al., 2007). Significant inter-individual variability and 
great inter-species differences in liver functions, that make animal models inadequate for 
the safety testing of drugs and xenobiotics, have produced the necessity to develop new in 
vitro models, able to better reproduce or mimic the function of the human liver. In the last 
decades this necessity has already stimulated intense research activity, sustained by 
significant financial investments. The development of methods (and models) alternative to 
animal experimentation, along with the approval of their use, either in basic research, or in 
the more complex field of pharmaco-toxicology, has known a noteworthy expansion in the 
last twenty years2 (see Table 2). 
                                                                
2 “Alternative” methods and the 3R’s principle.  
In 1959, Russel and Burch introduced, for the first time, the concept of methods “alternative” to 
experimental animal models (Russel & Burch, 1959). The authors defined as “alternative” any method 
that can be used in order to Replace, Reduce and Refine (3R’s principle) the use of animals in biomedical 
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Fig. 2. Schematic representation of the principal liver’s functions. 
However, due to the high level of specialisation and complexity of the hepatic parenchyma, 
with its specific intra-lobular “zonal” organisation (Christoffles et al., 1999), and given the 
peculiar sensibility of its cellular elements to even minimal environmental changes, none 
among the traditional and more widespread in vitro liver-derived models routinely 
available, seems to possess satisfactory features to be considered as a suitable model of the 
organ in vivo (Brandon et al., 2003; Guillouzo & Guguen-Guillouzo, 2008). New approaches 
require, actually, the generation (and validation) of human-specific in vitro liver-derived test 
                                                                                                                                                                   
research, testing or education. The basis of the 3R’s principle is the aim to improve ethical standards 
and animal welfare in in vivo experimental procedures, by: i) replacing, as much as possible, in vivo 
models (use of alternative methods, i.e. in vitro, ex vivo and in silico approaches), ii) reducing the number 
of animals needed for experimental objectives, and iii) refining the experimental procedures, in order to 
reduce animal sufferance (pain, stress, discomfort). Until now, despite the great political and 
economical efforts that have been undertaken worldwide during the last two decades (especially by EU, 
US and other industrialised countries, such as Canada and Japan) to comply with the 3R’s strategy 
(Mazzoleni and Steimberg, 2010; Hartung, 2010), only few alternative methods have been validated for 
regulatory toxicology and efficacy testing of chemicals. The Organization for Economic Co-Operation 
and Development (OECD), which represents 30 countries in the Americas (including the United States), 
Europe, and Asia, provides a collection of internationally harmonized testing methods for a number of 
toxicological endpoints using in vivo, in vitro, and even alternative approaches (OECD “Guidelines for 
the Testing of Chemicals”). For up-to-date information on the Alternatives to Animal Testing, see also 
“Altweb - the Alternatives to Animal Testing Web Site” http://altweb.jhsph.edu/), and, for specific 
bibliography, “ALTBIB - Resources on Alternatives to the Use of Live Vertebrates in Biomedical 
Research and Testing” at http://toxnet.nlm.nih.gov/altbib.html. On the web, AltTox.org, is a website 
dedicated to advancing non-animal methods of toxicity testing through online discussion and 
information exchange (http://alttox.org/). 
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Method 
------------------------------------- 
Remark 
 
In vitro 
(cell-based 
studies) 
In vivo 
(animal-based 
studies) 
Human clinical 
trials 
(volunteers) 
Evidence-based 
toxicology, 
human exposure, 
epidemiology 
Reliability  
of the predictive
studies 
single 
organ/tissue 
+/- +/- ++ +++ 
whole human 
population: 
multifactorial 
aspects, sex, race,
age, healthy or 
pathological 
conditions 
- - +/- +++ 
Capability to mirror whole 
organism’s response 
(systemic response, immune and 
hormonal regulation; all aspects 
of ADMET and DIDs) (*) 
-- +++ +++ +++ 
Specific toxicity assessment 
(targeting liver-specific effects 
and “zonal” toxicity) (**) 
-/+ ++ ++ ++++ 
Range of lethal and non lethal 
endpoints (acute toxicity) 
+++ 
(IC50) 
++ 
(DL50 + LOEL) 
-- Not applicable 
Chronic toxicity assessment - ++ +/- +++ 
Wide-range investigations 
(time-/dose-dependent studies 
without inter-individual 
variability, repeated-dose effects, 
etc.) 
+++ ++ - +++ 
Complex mixtures testing +++ +++ - + 
Mechanistic studies +++ ++ +/- 
+/- 
(macroscopic 
effect) 
Reproducibility 
(control of experimental/testing 
conditions) 
+++ +/- +/- - 
Validation of the systems 
+ 
(some 
endpoints) 
+ + Not applicable Not applicable 
www.intechopen.com
 
The Continuum of Health Risk Assessments 166 
Method 
------------------------------------- 
Remark 
 
In vitro 
(cell-based 
studies) 
In vivo 
(animal-based 
studies) 
Human clinical 
trials 
(volunteers) 
Evidence-based 
toxicology, 
human exposure, 
epidemiology 
Ethical features 
(3R’s principle; environmental 
reduction of potentially toxic 
wastes, etc.) 
+++ - + +++ 
Cost + ++++ ++++ ++ 
General remarks 
Validated 
models are 
still 
insufficient 
to be fully 
predictive 
for humans 
Animal use, 
even if still 
necessary, 
should be 
reduced as 
much as 
possible 
Should be 
performed after 
exhaustive pre-
clinical studies 
on accurate/ 
validated models 
By reducing pre-
clinical, clinical 
and post-clinical 
toxicity, 
epidemiological 
studies could be 
reduced 
(*) ADMET: absorption, distribution, metabolism, excretion, and toxicity; DIDs: drug-drug interactions. 
(**) Zonal toxicity: specific peri-central/peri-portal toxic effects (Allen et al., 2005). 
Table 1. Comparison of the various liver models employed in hepatotoxicity studies. 
model systems, which are able to give answers at the physiological level, and to be relevant 
to human outcomes. While consistent evidence demonstrates the breaking points of 
traditional in vitro models (static culture in monolayer) in reproducing the behaviour and 
physiological response of various tissues (the hepatic one, in particular), contemporarily, 
three-dimensional (3D) systems are achieving an increasing status (Mazzoleni et al., 2009). In 
effect, the more promising results seem, at present, to derive from the 3D techniques of 
culture, that, by guaranteeing the preservation of at least some characteristics of the complex 
hepatic microenvironment, can favour cell survival and the in vitro expression of the liver-
specific differentiated phenotype, allowing, in such a way, the generation of more reliable 
and predictive hepatic test models for human investigations (Shvartsman et al., 2009). 
In the present chapter, the principal models available for the in vitro study of liver functions 
are reviewed. Moreover, the contribution of new emerging technologies and tissue 
engineering, as basis for the conception of innovative hepatic models, the relevance of 3D 
bio-constructs, as reliable liver analogues, and their relative advantages and drawbacks in 
the process of being developed/validated, is discussed. A particular attention is given to the 
model systems based on the use of dynamic bioreactors, and, more specifically, on the use of 
the Rotary Cell Culture System (RCCS™, Synthecon, Inc.) device. 
2. Currently available liver-derived in vitro models and the role of liver-
specific microenvironment 
The need for studying hepatic functions, and for elucidating the molecular mechanisms at 
their basis, has resulted, over time, in the development of a huge number of liver-derived 
models and systems, that has not been equalled in the case of any other human organ/tissue 
(see Table 2). 
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Models Advantages Drawbacks References 
Human liver-derived 
single enzymes, 
supersomes, sub-
cellular and organelles’ 
fractions  
(cytosol, microsomes, 
mitochondria, S-9 
fractions) 
- Useful for identifying 
mechanisms/enzymes/ 
metabolism of drug- and chemical-
induced hepatotoxicity 
- Contain a rich variety of metabolic 
enzymes for studying the in vitro 
metabolism of drugs 
- High availability  
- Easy to prepare, use and store 
- Mitochondrial dysfunctions and 
energy metabolism studies are 
allowed 
- Molecular/sub-cellular 
investigations 
- Only sub-acute/acute toxicity studies 
- Extremely simplified models, lacking 
whole gene regulation systems, cell-
cell interactions, bile canaliculi, 
transporters, cell structures and 
functions 
- For extrapolation to whole cell, all 
sub-cellular fractions should be 
tested 
- Low level of enzyme activity may be 
faced 
- Difficult extrapolation to whole in 
vivo organism 
- Lack of concordance with the in vivo 
situation (microsomes lack some 
phase II enzymes) 
 
Boelsterli & 
Lim, 2007 
Clarke & 
Jeffrey, 2001 
Guengerich, 
1996  
Mae et al., 2000 
Rawden et al., 
2005 
 
Reporter gene-based 
systems  
(mainly P450 enzymes-
expressing models): 
recombinant hepatoma 
cells, liver supersomes, 
microsomes 
- Supply drug-metabolizing or 
functional capacity to cellular 
systems lacking metabolic 
enzymes/ transporters  
- Provide information about single 
CYP enzymes  
- Readily available 
- All known human cytochrome 
P450 (CYPs) have been 
successfully over-expressed in 
genetically modified organisms 
- Only sub-acute/acute toxicology 
studies 
- Lack of other phase I and phase II 
biotransformation enzymes 
- Extremely simplified model 
- The transduced isoform is in excess 
as compared to physiological 
concentration in vivo 
Huang et al., 
2000 
Single liver cells 
analysis 
- Single cell approach of biological 
process 
- High availability of cells 
- Possibility to test high broad 
number of drugs in various culture 
conditions 
- Very short-term studies 
- Sub-acute/acute toxicity studies 
- Need optimisation of investigation 
tools 
O’Brien et al., 
2006 
Xu et al., 2004 
Isolated hepatocytes in 
suspension 
- Highly available  
- Easy-to-handle 
- Poor functional activity  
- Applicability to High-throughput 
screening (HTS): limited 
- Could support kinetic, and drug-
drug interactions studies  
- Short-term cell viability (2-4 hrs) 
- Sub-acute/acute toxicity studies 
- Phenotypic instability due to 
alteration of tissue architecture and 
ECM, loss of cell 
polarisation/organisation  
-  Loss of cell-cell / cell-ECM 
interactions  
- High variability between batches 
- Absence of non-parenchymal cells 
Guillouzo, 1998 
Richert et al., 
2006  
Hepatic cell lines in 
conventional 2D culture 
(examples of human-
derived cell lines: 
HepG2, Hep3B, 
HepaRG, HepZ, 
C3A,THLE;  
examples of non-
human hepatic cell 
lines: HTC, BRL3A and 
NRL clone 9, Fa32 and 
WIF-B9) 
- Almost infinite capacity of 
proliferation 
- High availability 
- Easy-to-handle (culture, freezing, 
etc.) 
- Possibility to genetically engineer 
cells (Hep3B, HepaR, THLE) 
- Avoid repeated cell isolation 
- High reproducibility 
- Moderate cost  
- Applicable to HTS 
- Differentiated phenotype variably 
expressed, according to the cell line 
(e.g. HepG2 cells express CYP1A, 
- Acute toxicity studies 
- Lack or limited/partial drug-
metabolism capacity and other 
hepatic functions 
- Absence of non-parenchymal cells 
- Expression of typical phenotype, 
depending on culture conditions and 
passaging 
- No accurate modelling of in vivo 
hepatic phenotype (genetically 
instable and/or derived from 
malignant tissues) 
Boess et al., 
2003  
Dierickx, 2003 
Guillouzo et al., 
2007 
Jennen et al., 
2010 
Kanebratt & 
Andersson, 
2008 
Malatesta et al., 
2008 
Payen et al., 
1999 
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Models Advantages Drawbacks References 
CYP2B, CYP3A, CYP2E, UDPGT, 
GST, but lack other drug 
metabolizing enzymes; HepRG cells 
express CYP1A2, CYP2B6, CYP2C9, 
CYP3A4, CYP2E1, GSTAs, 
UGT1A1, some ABC transporters, 
some plasma proteins, but not 
always in homogeneous way) 
- According to the cell line: metabolic 
profiling; kinetic studies; drug-drug 
interaction, mechanistic studies and 
short-term toxicity screening 
Richert, et al., 
2006  
Schoonen et al., 
2009 
Slany et al., 
2010 
Werner et al., 
2000  
Wilkening & 
Bader, 2003 
2D primary cultures of 
hepatocytes in static 
conditions (monotypic 
cultures) 
- Primary human hepatocytes 
represent the in vitro model of 
choice for drug screening 
- Express most of CYP isoforms (e.g. 
CYP1A2, CYP2A6, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, 
CYP2E1, CYP3A4)  
- Express phase II biotransformation 
enzymes (e.g. UDPGT, SULT2A1, 
GST) 
- Easy to use and fast  
- Short-term preservation of cell 
viability, liver-specific functions and 
gene responsiveness  
- High/medium efficient 
cryopreservation 
- At high density or confluence, cell-
cell contacts may be rebuilt 
- Reproducible method 
- Short-time inducibility of phase I 
and phase II enzymes by 
xenobiotics  
- Applicable to HTS 
- Could support: metabolic profiling, 
pharmacokinetic (ADME) and 
drug-drug interactions (DIDs) 
studies, mechanistic studies and 
short-term toxicity screening 
- Early phenotypic alterations (about 
75% of total CYP activity within the 
first 24 hrs)= loss of accuracy 
- Scarcity of human liver 
- Isolation is time consuming and may 
damage cells 
- Limited proliferation 
- Difficulty to mimic the in vivo 
microenvironment 
- Loss of cell polarity, tissue 
architecture, membrane domains  
- Lack of non-parenchymal cell types 
- Inter-donor variability (human liver) 
- Batch-to-batch variability of isolated 
hepatocytes 
- High influence of culture conditions 
on cell features  
- Inter-species variability  
Gomez-Lechon 
et al., 2007 
Guillouzo, 1998  
Hewitt et al., 
2007 
Lecluyse et al., 
2001 
 
Somatic cells 
(trans-differentiation 
into hepatocytes), 
hepatic stem/ 
progenitor cells 
- Could express a large panel of 
liver-specific genes (including 
those involved in 
biotransformation processes)  
- A great effort is needed to reach a 
fully differentiated phenotype and 
for use in risk assessment 
- Variability in the phenotype 
expressed by “hepatocytes“ 
Lee et al., 2004  
Schwartz et al., 
2002 
 
2D co-cultures of liver-
derived cell types 
(heterotypic culture, at 
large- or at micro-scale) 
- Higher cell viability than 
monotypic culture (2 weeks) 
- Maintain some hepatic functions 
for longer time (plasma protein, 
urea secretion, lipoprotein 
metabolism, some CYPs) 
- Maintain heterotypic cell-cell 
interactions 
- Only some liver specific functions are 
slightly maintained after longer time 
in culture (up from 7 to 15 days) 
Guzzardi et al., 
2009 
Ijima et al., 2005  
Khetani & 
Bhatia, 2008 
Ohno et al., 
2008  
3D cultures of primary 
hepatocytes/hepatic cell 
lines/stem cells without 
(spheroids, 
- Maintain more hepatic functions for 
longer time (up to some weeks) 
- A number of genes are up-regulated 
(albumin, transferrin, fibrinogen, 
- Cell recovery is sometimes difficult  
- Loss of liver-specific functions 
(decline of some CYP activities) 
- In some 3D models, formation of 
Chang & 
Hughes- 
Fulford, 2009  
Du et al., 2008 
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Models Advantages Drawbacks References 
micromasses) or with 
scaffolds  
(micropatterned 
polydimethylsiloxane 
surfaces; nanofibrillar 
network; hydrogels 
Sandwich cultures: 
collagen-collagen, 
collagen-matrigel, 
alginate encapsulation, 
or RGD-galactose)  
prothrombin, CYP1A1, CYP1A2, 
CYP2E1, CYP3A, etc.) 
- Ureagenesis varies according to the 
model, and may be 6-7 times as in 
classical 2D culture 
- High level of hepatic transporters 
- Fluidic dynamic of some bioreactor 
favours shear stress and support 
liver-specific gene expression 
- Improve microenvironment 
features 
- Hepatocytes are much more 
sensitive to some xenobiotics than 
in static 2D culture 
- After optimisation of culture and 
microenvironment conditions, these 
models could be used for chronic 
toxicology 
necrotic cores:  
- According to the 3D model, specific 
hepatic function are maintained 
- Currently unsuitable for HTS (need 
the development of adequate 
methods/devices for increasing 
sensitivity and reliability, lowering 
cost and time-consuming features) 
Evenou et al., 
2007 
Kienhuis et al., 
2007 
Liu Tsang et al., 
2007  
Maguire et al., 
2007 
Meng, 2010 
Miranda et al., 
2010 
Suzuki et al., 
2008 
Walker & 
Woodrooffe, 
2001 
3D co-cultures of liver-
derived cell types 
- Longer cell viability, as compared to 
monotypic 3D culture (up to 57 
days) 
- Sustain some liver-specific function 
from 3 days  to 7 up weeks 
(albumin, urea secretion, expression 
of CYP1A1/2,CYP2B1, CYP3A) 
- Mimic liver cyto-organisation/cyto-
orientation 
- Intercellular interactions and 
communications 
- Soluble factors enhance hepatocytes 
functions 
According to culture conditions: 
- variable cell viability and 
differentiation status 
- need bioreactor optimisation to 
increase mass transfer  
- in situ approaches/techniques need 
to be developed to be applicable for 
HTS (see 3D monotypic cultures)  
Bennett et al., 
2006 
Bhatia et al., 
1999 
Cheng et al., 
2008 
Leite et al., 2011 
Ohno et al., 
2008 Riccalton-
Banks et al., 
2003 
Precision-cut liver 
slices 
- Several aspects of in vivo 
microenvironment are preserved 
- Retain in vivo cyto-/histo-
architecture 
- Acinar sub-localization of functions 
- Cellular heterogeneity (include non-
parenchymal cells) 
- Expression of functional drug 
metabolizing enzymes (CYP1A, 
CYP2A, CYP2B, CYP2C and CYP 
3A sub-families) and transporters 
- Preservation of hepatocyte polarity 
-  Could support metabolic profiling, 
mechanistic studies and, less easily, 
toxicity screening 
- Short-term viability (about 5 days) 
- Short-term metabolic studies (about 
48 to 72 hrs) 
- Progressive formation of necrotic 
cores  
- Poorly amenable to HTS 
- Limited liver-specific functions  
- Scarcity of human liver donors 
- High intra-assay variability  
- Donor–to-donor variability 
- Hard to handle 
- Poorly efficient cryopreservation 
- Poor diffusion of drugs across the 
slides 
Elferink et al., 
2008 
Krumdieck, et 
al., 1980  
Lake et al., 1996 
Schumacher et 
al., 2007 
 
Isolated perfused liver 
(resections/whole 
animal liver) 
- Maintenance of whole organ 
features and functionality (cell-cell 
and cell-ECM interactions, cell 
polarisation, cell heterogeneity, 3D 
organisation, zonation) 
- Represent the closest models 
mimicking in vivo situation 
- Allow real-time bile 
collection/analysis and oxygen 
consumption 
- Liver injury is reflected by LDH, 
AST, and ALT 
- Very short-term studies are possible 
(2-3 hours) 
- Hard to handle 
- Expensive model 
- Poor reproducibility 
- Difficult inter-species extrapolation  
- Impossibility to be applied to human 
liver 
Gores et al., 
1986 
şahin, 2003 
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Models Advantages Drawbacks References 
Integrated discrete 
multiple organ co-
culture systems 
- Try to re-create the organ-organ 
cross talks (paracrine factors) 
- Assessment of organ-specific 
toxicity 
- Short-term (48 hrs) assessment of 
the biological/toxicological effect 
of native drugs and their 
metabolites/catabolites 
- Need optimisation for HTS 
- Biotransformation of drug need to be 
known earlier to optimise cell culture 
and spatial organisation (or 
determined by random positioning) 
- Some limitations related to the 2D 
configuration 
Li, 2008 
and 2009 
Whole organism 
- Maintenance of systemic 
interrelations, tissue integrity and 
normal hepatic functions (for the 
considered specie) 
- Maintenance of liver physiology 
- Well known and often 
standardized methods 
- Whole system inter-relation is 
preserved 
- Allow to take into account the 
biokinetic features of 
drugs/molecules, 
(ADME/toxicology processes are 
maintained) 
- Ethically discussable 
- Need to be revised for applying the 
3R’s concept 
- Need of GPL practice 
- Inter-species variability and difficulty 
to reflect human context (human-
specific metabolites, inherent 
sensitivity of peculiar population) = 
difficulty and risk of unreliability, 
extrapolation of results from animal 
to human for xenobiotic metabolism 
as well as target organ sensibility 
- In clinical trials: inter-individual 
variability, limitations of trial 
endpoint and population sampling  
- Expensive and time consuming  
- Uncontrolled sources of variability, 
such as housing conditions of 
animals, subjectivity in scoring, etc. 
 
Li, 2004 
 
New computational (in silico) models, toxicogenomics-, transcriptomics-, proteomics- and 
metabolomics-based models present important advantages for risk assessment, but they need adequate 
in vivo or in vitro models to be reliable (Cheng & Dixon, 2003; Khor et al., 2006; Hunt et al., 2007; Valerio, 
2009; Amacher, 2010; Gómez-Lechón, et al., 2010). 
Table 2. Experimental approaches used for hepatic risk assessment. 
The first and simplest in vitro liver models were optimised for studying single metabolic 
functions, and are based on the use of hepatic sub-cellular fractions (single enzymes, 
microsomes, supersomes, cytosolic fractions and mixed fractions). Although such models 
are easy to use, they fail in mimicking the complete and complex metabolic potential of 
hepatocytes, as well as intra-lobular zonal specialisation and inter-individual heterogeneity 
of the liver-specific cell phenotype. Not even the models based on the use of liver-derived 
cell lines are considered to be fully reliable, even though, for their metabolic characteristics, 
they are more complete than the sub-cellular fractions, and present the advantage of 
limitless culture time. These cell lines, generated from malignant tumours or obtained from 
transformed cells, present, in effect, the disadvantage of having lost the majority of their 
original phenotypic features. 
In the same way, also engineered cells or systems (e.g. microsomes) based on reporter gene 
transfer have been shown to be not sufficiently reliable and informative (for more 
exhaustive information on the principal in vitro hepatic models traditionally in use, see also 
Brandon et al., 2003, Zucco et al., 2004, Gómez-Lechón et al., 2007, Guillouzo & Guguen-
Guillouzo, 2008). 
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It is now well recognised that any experimental model that has to be used for reproducing in 
vitro the function of human liver, must be developed from human hepatocytes in primary 
culture (Gómez-Lechón et al., 2007). The scarce availability of tissue, its variable quality, and 
the difficulty to succeed, with the traditional techniques, in maintaining isolated hepatocytes 
in vitro, preserving their viability and functions for long-term studies, have strongly 
hindered the refinement of these models, limiting, in such a way, the significance of their 
use (Gómez-Lechón et al., 2007; Guillouzo & Guguen-Guillouzo, 2008). No result worthy of 
further consideration has been derived from the very large number of attempts performed 
to get well-differentiated hepatocytes from stem precursors, either originating from the liver 
itself (resident hepatic progenitors), or from extra-hepatic sites (e.g. bone marrow and 
adipose tissue), or from mesenchymal cells, obtained in precocious phases of the 
development (cells from umbilical cord blood or embryonic stem cells) (Cantz et al., 2008). 
Advantages and limits of these cells as “hepatocyte donors” are summarized in Table 3. 
 
Cell type Origin Characteristics Reference 
Embryonic 
stem cells 
(ESCs) 
Derived from 
the inner cell 
mass of pre-
implantation-
stage 
blastocysts 
 Totipotent stem cells 
 Self-renewal 
 Huge proliferative potential 
 High differentiation potential and plasticity 
 Expression of early markers of hepatic 
differentiation  
 Some mature hepatic functions are maintained  
 Difficulty to be regulated and maintained under 
controlled conditions 
 Risk of oncogenicity 
 Ethical issues 
 Limited availability 
Agarwal et al., 2008 
Baharvand et al., 2006 
& 2008 
Ishii, et al. 2010 
Jozefczuk et al., 2011 
Liu T et al., 2010 
Rambhatla , et al., 
2003 
Soto-Gutierrez et al., 
2007 
Extra-hepatic 
adult stem 
cells  
Bone marrow 
 Pluripotent stem cells 
 Inducible to express a number of liver-specific 
functions 
 Difficulty to reach full adult hepatocyte 
phenotype 
 Less differentiated than primary hepatocytes 
Avital et al., 2001 
Chen et al., 2006 
Chivu et al., 2009 
Petersen et al., 1999 
Adipose tissue 
 Pluripotent stem cells 
 Express to some extent specific hepatic functions 
 Quantitatively less differentiated than HEPG2 
cell line 
 Less differentiated than primary hepatocytes 
Okura et al., 2010  
Umbilical cord 
blood  
 
 Pluripotent stem cells 
 Express some hepatic markers 
 Further investigations are necessary to better 
characterize their differentiation status 
 Less differentiated than primary hepatocytes 
Campard et al., 2008 
Hong et al., 2005 
Lee et al., 2004 
Peripheral 
blood 
 CD14+ peripheral blood monocytes 
 Well differentiated hepatocyte-like cells 
(expression of a number of liver-specific 
functions) 
 Easy to obtain 
 Multi-laboratory investigations should be done 
to validate the method 
Ruhnke et al., 2005 
Ehnert , 2008 and 
2011  
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Cell type Origin Characteristics Reference 
Adult/foetal 
stem cells 
and hepatic 
progenitors 
Liver 
 Multi-potent stem cells 
 Different adult stem cells typologies 
 Still difficult to use for therapeutic applications 
 Hardly obtainable 
Dan & Yeoh, 2008 
Turner, 2011 
Hepatic 
progenitors 
(usually 
localised in 
small biliary 
canals) 
 Bi-potential cells 
 Differentiate in both hepatocytic and biliary 
lineages  
  Low cell number (in adult liver) 
  Difficult proposal for human derived cells  
Dan & Yeoh, 2008 
Zhang et al., 2008  
Foetal 
hepatocytes, 
hepatoblast 
precursors 
 Multi-potent stem cells 
 High proliferation rate 
 Exhibit some biotransformation pathways 
 Bi-potential plasticity 
  Ethical problems for human donors  
Dan et al., 2006, 
Ring et al., 2010 
Somatic adult 
cells: 
hepatocytes 
 Temporary high differentiated phenotype  
  Unipotent cells 
  Low replication rate 
  Rapid cell function decrease  
  Low cell availability for human cells 
Gomez-Lechon et al., 
2007 
Induced 
pluripotent 
stem cells 
(iPS) 
From 
connective 
tissues  
(fibroblasts or 
other somatic 
cells) 
 Pluripotent cells 
 Highly proliferative cells 
 Capability to differentiate into liver-specific 
parenchymal cells 
 Quite similar to hESCs 
 Very promising technology 
 Lowest replication and differentiation capability
than ESCs  
 Immature and incomplete hepatic phenotype 
 Still need the optimisation of differentiating 
protocols 
 Development of iPS without virus could 
represent a great challenge also for therapeutic 
applications 
 Need further development of differentiating 
strategy (type of differentiating factor to be 
used, spatio-temporal release of factors), 
optimisation and standardisation of induction 
protocols and culture conditions, as well as an 
increase of the quality control of the final cell 
preparation 
Takahashi et al., 2007 
Espejel et al., 2010 
Hu et al., 2010 
Q. Feng et al., 2010 
Sullivan et al., 2010 
H. Liu et al., 2010 & 
2011 
Greenbaum, 2010 
Si-Tayeb et al., 2010 
Trans- 
differentiated 
cells 
Epithelial cells 
 Bi-potent cells 
  Immature cell functions are expressed Snykers, 2007  
Pancreatic cells 
(healthy or 
tumour-
derived) 
 Some differentiated hepatic enzymes are 
expressed 
 Difficult to propose for human-derived cells 
Tosh , 2002 
Burke et al., 2006 and 
2007 
 
Table 3. Cell types commonly used for the design of in vitro hepatic models and liver tissue 
engineering. 
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The hepatocyte is a structurally complex epithelial cell and represents the major hepatic 
parenchymal cell type, either in terms of mass (60% of the total number of liver cells and 
80% of the total volume of the organ), or for the number of functions carried out. 
Cholangiocytes and non-parenchymal cells [sinusoidal endothelial cells, stellate cells (fat-
storing Ito cells), pit cells (intrahepatic lymphocytes), Kupffer cells, and hepatocyte 
precursors] influence, by their presence and activity, hepatocyte survival and function 
(Selden et al., 1999; Riccalton-Banks et al., 2003; Nahmias et al., 2006; Catapano & Gerlach, 
2007). The extracellular matrix (ECM) represents another key component of this organ: it is 
peculiar by composition and structure, and it plays a determinant role in regulating 
hepatocyte viability, as well as other biological processes, such as development, 
proliferation, migration and functional activity (Selden et al., 1999; Van de Bovenkamp et al., 
2007). Being functionally and structurally polarised, the hepatocyte requires, in effect, 
precise and specific cell-cell and cell-matrix interactions. The characteristic cyto-architecture 
of liver, organised as “lobular” units, entails, furthermore, a particular morphological and 
functional specialisation of hepatocytes, that varies with position along the liver sinusoid, 
from the portal triad to the central vein (“zonation”) (see Fig. 1 and Fig. 3). It is now well 
accepted that this regional compartmentalisation of metabolic (and detoxification) functions 
of hepatocytes within the “acinus” is responsible for the “zone-specific” liver susceptibility 
to many hepatotoxic agents (Lindros et al., 1997). The hepatocellular “zonation”, sustained 
by portocentral patterns of gene expression (“gradient” versus “compartmental” and 
“dynamic” versus “stable” types of zonation), is modulated by chemical gradients of oxygen, 
hormones, growth factors and metabolites, which are generated and maintained as a result 
of the specific characteristics of the ECM and of the distribution of non-parenchymal cells 
(Gebhardt, 1992; Christoffels et al., 1999). This specific microenvironment, dynamic, highly 
organised and rigidly structured, is thus fundamental for maintaining hepatic functions. It 
is, actually, well known, how the subversion of liver architecture produced by the 
alteration/destruction of the strict relationship hepatocyte-matrix and hepatocyte-non 
parenchymal cells, that occurs as a consequence of trauma or pathological states (e.g. 
fibrosis), is responsible for important negative effects on liver homeostasis and loss of 
functions (Selden et al., 1999; Van de Bovenkamp et al., 2007). Experimental models of liver 
should, therefore, take into account the strict inter-dependence between the complex histo-
morphology of this organ and its functions/responses (Allen et al., 2005). 
The need to preserve the original cytological and histo-architectural features of the hepatic 
tissue has provided the basis for attempting to develop various ex vivo hepatic models 
(Table 2). Among these models, the best known is the isolated and perfused organ model 
(Gores et al., 1986, Bessems et al., 2006). Although this model is considered to be the closest 
representation of the in vivo situation, its use is limited to a few hours; moreover, the 
necessity to employ a whole organ for each single experimental point, leads to a very broad 
range of variability in the results (Gores et al., 1986), and makes impossible the use of 
human-derived tissue. As an alternative, the model based on the culture of organ slices, 
obtained by particular section methods (precision-cut liver slices) has been developed. 
Notwithstanding this model may solve, at least partially, the problem of results’ variability, 
it still presents, employed with the conventional culture techniques, the disadvantage of 
limited cells’ survival (only a few days), even if slice thickness is maintained under the 
physical limit of diffusion of gas and nutrients (200 µm) (Fisher et al., 2001, Vickers et al., 
2011). Despite the development of new dynamic culture methods (see later) renders the  
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Fig. 3. Zonal specialisation of liver acinus, from periportal to centrolobular region, and 
different susceptibility to toxic agents. 
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future of this model very promising, due to the fact that, by preserving intact the original 
tissue microenvironment (ECM, multi-cellularity and histo-architecture), it could be very 
close to the liver in vivo (Van de Bovenkamp et al., 2007), liver slices do not possess, at 
present, such characteristics. The more ordinary models used in the study of hepatic 
function, with their relative advantages/disadvantages, are illustrated in Table 2. 
3. Three-dimensional liver-derived in vitro systems: Tissue engineering and 
the contribute of the new technologies 
As in the case of other tissue models, it is now generally accepted that any attempt aimed at 
the generation of reliable and physiologically relevant in vitro liver analogues, should take into 
account the need of reproducing (or conserving) the specific characteristics of the original 
microenvironment typical of that organ (see above). The main features of the environmental 
context within which cells physiologically grow, proliferate and express their own functions, 
include, in addition to multiple cellularity, biochemical and mechanical properties (that are 
specific of each organ/tissue), also the three-dimensionality (Mazzoleni et al., 2009).  
Over the last few decades, it has already been widely demonstrated that, compared to the 
use of traditional culture techniques in monolayer (2D), three-dimensional (3D) culture 
methods allow researchers to generate in vitro tissue-derived model systems that better 
mimic the in vivo situation (Pampaloni et al., 2007). Significant differences have, in fact, been 
demonstrated between the biological behaviour of cellular elements (hepatocytes included) 
maintained in culture with traditional (2D) culture methods, and that of cells kept in 3D 
culture (Mazzoleni et al., 2009). Figure 4 presents a qualitative comparison between the most 
important characteristics of the different currently used liver model systems. 
The importance of being able to reproduce in vitro the 3D specific microenvironment typical 
of the tissue of origin, has led to the design and development of increasingly complex and 
sophisticated 3D culture methods. These methods, benefiting also from the rapid 
development of tissue engineering techniques, have produced, especially in the case of the 
liver, an extremely wide variety of models (Nahmias et al., 2006). In the case of the liver, due 
to the high structural complexity of its tissue microenvironment (see above), any attempt to 
apply the principles of tissue engineering aimed to generate constructs capable of 
reproducing, in vitro, the specific characteristics of the organ in vivo, implies to face 
extremely difficult technical problems, which also result from having to consider issues that 
must be performed on spatial and temporal scales that are “gigantic”. For example: the 
hepatocyte can recognize the structural characteristics of the surface on which it must 
adhere with a threshold of nanometers in size, but it should organise itself in hierarchical 
structures of centimetres in size; similarly, the presence of particular molecules may alter the 
structural characteristics of the hepatocyte’s microenvironment within a few milliseconds, 
while the time required for the cell to functionally adapt to these changes can take several 
weeks (Mitzner et al., 2001). 
Over the years, the research in this direction has been mainly devoted to the generation of 
new materials (micro- and nano-structured), which possess physical and biochemical 
characteristics suitable to fulfil mechanical and biological support to the physiological 
hepatocyte activities. In particular, also due to the contribution of the new emerging 
technologies, the number of liver models that have been generated within the last ten years, 
by using the principles of tissue engineering, has been enormous. 
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Fig. 4. Comparison of the most diffused hepatic model systems. Primary hepatocytes 
cultured in monolayer represent the most diffused model. * HTS: suitable for high-
throughput screening.  
Since differentiated hepatocytes are anchorage-dependent, immotile and non-proliferating 
cells, the first “liver-like engineered microenvironments" had, as primary objective, to ensure 
well-defined characteristics of the substrates (bio/artificial matrices), in terms of architecture 
(nano-fibrillar), porosity (micro- and macro- scale), and biochemical composition. The 
products that are now available (even commercially), are hydro-gels and 3D surfaces, 
composed of specific constituents of original extra-cellular matrices (extractive or synthetic 
origin), and solid supports (micro-carriers or scaffolds, also pre-shaped), made up of porous, 
bio-compatible, organic or synthetic components. Examples of the sophisticated models that, 
for various purposes, have been obtained from primary hepatocytes, are those generated by 
using bio-degradable nano-structured substrates (Kim et al., 1998), heat-sensitive polymers 
(Ohashi et al., 2007), various 3D matrices (Fiegel et al., 2008; ZQ. Feng et al., 2010; Ghaedi et al., 
2012), or synthetic self-assembling hydrogels (Wang et al., 2008). 
The development of the micro- and nano-technologies (i.e. micro-/nano-fabrication 
techniques, micro-electronics and micro-fluidics), has allowed the creation of models where 
the cellular elements are integrated into controlled microenvironments, within which, in 
addition to the precise definition of the spatio-temporal signals individual cells are exposed 
to, it is also possible to perform the continuous multi-parameter monitoring of their 
biological responses ("lab-on-a-chip" devices). Representative examples of this approach, 
applied to cultured hepatocytes, and aimed at generating functional models of liver lobules, 
bile canaliculi and sinusoids, have been given, respectively, by Ho et al. (2006), Lee et al. 
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(2007), and, more recently, by Nakao et al., 2011. Although structurally very complex and 
interesting, these models of "micro-structured tissue-like environments" have major 
drawbacks, that limit significantly their application: they lack, in effect, the complexity of 
original tissue-specific microenvironments, which are typical of the situation in vivo; 
moreover, they do not allow cell survival for time periods higher than several hours or days. 
4. Bioreactors and relative microgravity condition 
It is well known that the metabolic requirements of complex 3D cell constructs are 
substantially higher than those needed for the maintenance of traditional cell monolayers 
(2D culture) kept in liquid media under static conditions. 
The first "dynamic" bioreactors were, in effect, designed in order to meet the necessity of 
increasing the "mass transfer" rate, for facilitating an adequate long-term supply of gases 
and nutrients (and the removal of metabolic waste) up to the cellular elements placed in the 
inner parts of complex 3D tissue explants or tissue-like constructs. Taking advantage of the 
great progress in the development of new technologies, and of the contribution of 
computational fluid dynamics, a wide array of dynamic bioreactors have been devised 
(from the simplest stirred- or suspension-based culture systems, to the more complex 
membrane-based reactors, and their more sophisticated versions, that include load-, 
continuously perfused-/pulsed-systems, and multi-compartmentalised bioreactors, able to 
generate highly controlled microenvironments) (Török et al., 2001, Martin & Vermette, 2005; 
Catapano & Gerlach, 2007; Meuwly et al., 2007, Guzzardi et al. 2011). However, despite all of 
these technological efforts, none of these bioreactors, are, at present, able to provide optimal 
conditions for the long-term maintenance of large tissue-like masses in culture. The current 
generation of bioreactors was, in reality, developed for yielding large masses of cells (or cell 
products) for industrial or clinical applications, and not for supporting the survival or the 
self-assembly of multiple cell types into complex 3D tissue-like structures (Hutmacher & 
Singh, 2008). This applies, in particular, to the liver, a highly specialized organ, whose 
cellular components are extremely sensitive to even minimal environmental changes, 
already under physiological conditions (Nahmias et al., 2006; Catapano & Gerlach, 2007). 
An important aspect, essential for the appropriate choice of the specific device to use for 
cell/tissue culture methods, is the consideration that, even if hydrodynamic forces 
effectively increase mass transfer, in dynamic bioreactors for 3D culturing this effect should 
be achieved by considering (and balancing) the detrimental effect of turbulence and shear 
stress on cell survival and function. Low-shear environment and optimal mass transfer have 
been attained only with the introduction of the Rotary Cell Culture System (RCCSTM, 
Synthecon, Inc.) bioreactors. This technology, fruit of N.A.S.A.’s Johnson Space Center 
technological research and optimised over the last ten years, has been successfully used in 
ground- as well as in space-based studies on a wide variety of cell types and tissues (a vast 
literature is available at http://www.synthecon.com). RCCSTM bioreactors provide several 
advantages, when compared to other available 3D culture systems (Mazzoleni & Steimberg, 
2010). A comparison of the main features of various bioreactors (static or dynamic flow 
condition) commonly used in the foremost culture techniques is presented in Table 4. 
Horizontally rotating, transparent clinostats, RCCSTM devices efficiently create a unique, 
highly controlled microenvironment that, by reproducing some aspects of microgravity 
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(simulated microgravity) (Klaus, 2001; Ayyaswamy & Mukundakrishnan, 2007), guarantee 
the most favourable conditions for cell and tissue culturing (Schwarz et al., 1992), and 
provide potentially powerful tools to reproduce specific 3D tissue morphogenesis 
(Mazzoleni et al., 2009). Complex tissue-like 3D constructs, different cell types from various 
origins and various intact tissue explants have been demonstrated, by our group and others, 
to be kept efficiently in culture by these bioreactors, even for long periods of time (Unsworth 
& Lelkes, 1998; Hammond & Hammond, 2001; Vunjak-Novakovic et al., 2002; Nickerson et 
al., 2007; Cosmi et al., 2009; Steimberg et al., 2009, Steimberg et al., 2010; Mazzoleni et al., 
2011). 
Figure 5 shows selected examples of RCCSTM-based tissue culture methods, developed and 
optimised by our group, and their advantages. 
 
 Shear stress 
Mass transfer 
(gas/nutrient 
supply; waste 
removal) 
Dimensionality 
Adequate for 
co-culture 
Maintenance of 
liver- specific 
phenotype 
Static 2D culture 
(monolayer) 
No Adequate 2D Moderately 
Few hours/ 
days 
Static 2D culture 
(on biosynthetic 
matrices) 
No Limited 
3D 
(limited) 
Moderately 
Few 
days/weeks 
Roller bottles Moderate Moderate 2D Poorly Few days 
Spinner flasks High High 
3D 
(very limited) 
Poorly 
Few 
days/weeks 
Microfluidic 
bioreactors 
Moderate/
High 
High 2D/ 3D Moderately 
Few 
days/weeks 
Perfused  
bioreactors 
High High 
3D 
(very limited) 
No Few weeks 
Zonation-based 
devices 
High Optimal 3D 
To some 
extent 
Several days 
Hollow fiber 
bioreactors 
Low High 
3D 
(very limited) 
To some 
extent 
Some days/ few 
weeks 
RCCS™  
bioreactors 
Low Optimal 3D Yes Some weeks 
Table 4. Static and dynamic bioreactor platforms used in 2D and 3D culture methods. 
Even in the case of liver models, it has been demonstrated how these bioreactors allow for 
the maintenance of isolated human primary liver cells and tissue explants in vitro, under 
conditions that preserve their viability and differentiated functional characteristics, even for 
long periods (several weeks). Khaoustov et al. (1999) have, for example, showed that human 
hepatocytes, adherent on small biodegradable substrates, were able to survive for 60 days, 
form specific junctional complexes and structures similar to bile canaliculi, and retain the 
ability to biosynthesize proteins. The microgravity-based culture conditions generated by 
the RCCSTM bioreactor have also proved to ensure the long-term survival and preservation 
of the differentiated metabolic functions in the case of isolated hepatocytes in monotypic 3D 
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culture (cellular spheroids) (Dabos, 2001), in co-culture with endothelial cells (heterotypic 
cultures), and in the more complex case of liver tissue homogenates, as well (Yoffe, 1999). 
Similar observations have also been reported by our group, proving that, under 
microgravity conditions, primary isolated hepatocytes organize themselves autonomously 
into multicellular spheroids, with properties similar, for many aspects, to normal liver cells 
in vivo (Mazzoleni et al., 2008). Finally, Wurm et al. (2009) have also described an interesting 
application of the RCCSTM technology for its possible use in the clinical field, as an 
alternative to conventional models of bioartificial liver (BAL). 
 
Fig. 5. Examples of RCCSTM-based tissue culture methods, developed and optimised by our 
group, and their advantages. 
5. Conclusions 
The 3D culture methods based on the use of the dynamic RCCSTM bioreactor demonstrates 
that they can guarantee the best conditions for generating in vitro microenvironments 
suitable for the long-term maintenance of viable liver-derived parenchymal cells and tissue 
explants. These techniques enable, moreover, to preserve some of the native and typical 
morpho-functional characteristics of the organ in vivo. For these reasons, the RCCSTM-based 
3D culture methods illustrated in this chapter present, in the current scientific context, the 
most promising prospect for the development of physiologically significant liver models, 
which may, in the future, be usefully employed in basic and applied research, in pharmaco-
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toxicology, risk assessment, and in clinical fields. Remarkably, the rapid progress in the 
development of new experimental protocols and analytical methods, together with the 
possibility of using this innovative microgravity-based culture technology for the 
development of liver-derived complementary in vitro models, based on the use of human 
isolated cells or intact tissue explants (healthy or pathological), could, indeed, open new 
perspectives for the study of important (and still unknown) aspects of the patho-physiology 
(functions and responses) of this complex organ. Once optimised (and validated), these in 
vitro (cell-based) and ex-vivo (tissue-based) human liver models should also allow new 
applications in the field of pharmaco-toxicology and risk assessment, and, in addition, could 
permit to reduce the need of experimental animals. By mimicking human liver functions 
and responses, these models could, in effect, be used either for studying mechanisms of 
toxicity (identification of critical toxicological pathways/targets), or, if adequately 
optimised, for screening purposes (Blaauboer, 2008). 
This is in line with the declared policies of the European Union (EU) and of the United 
States (US), which solicit more innovative approaches to toxicity testing and the reduction of 
animal-based studies, as it is well expressed, for example, by EU legislation (7th Amending 
Directive 2003/15/EC to Council Directive 76/768/EEC on Cosmetics; REACH Regulation 
on Chemicals and their safe use - EC 1907/2006, Council Regulation n.440/2008 on 
dangerous substances, and Directive 2010/63/EU on the protection of animals used for 
scientific purposes) (Lilienblum et al., 2008; Hartung, 2010), and by the 2007 landmark report 
of the US National Academy of Sciences “Toxicity Testing in the 21st century. A vision and a 
strategy” (NRC, 2007). The NCR 2007 report emphasizes the need of replacing traditional 
animal-based studies with innovative testing strategies (physiologically relevant in vitro 
assays and specific in silico models), which, taking advantage of new advances in scientific 
knowledge and new technologies, could improve real exposure measurement and human 
health risk assessment. The report envisions a shift of the traditional paradigm of toxicology 
from the measurement of apical endpoints in animal models, to the proper understanding of 
primary toxic mechanisms (“toxicity pathways”) in humans and use of computational 
modelling techniques (“in silico methods”). This vision has generated various research 
initiatives and several on-going projects, such as the HESI “Risk Assessment in the 21st 
Century” Project (RISK21) and the US Environmental Protection Agency (EPA)’s ToxCastTM 
program (Dix et al., 2007; US EPA, 2009), aimed at advancing toxicology strategies in EU and 
US (Vanhaeke et al., 2009; Stephens et al., 2012). According to NRC 2007 vision, predictive 
models that need to be developed, should be based on the identification, analysis and 
modelling of pathways involved in human cellular responses during the transition from 
physiological to pathological status in response to toxicants (US EPA, 2009). Innovative 
tissue-specific in vitro models (such as the 3D RCSSTM-based liver models described in this 
chapter can be considered), are intended to identify and evaluate key toxicity pathways 
perturbations (NCR, 2007), in order to create the knowledge base required to develop in 
vitro and in silico pathway assay test systems relevant to human risk assessment (Stephens et 
al., 2012). The specific interest that these 3D liver models present within this new vision in 
toxicological risk assessment is clearly highlighted by the US EPA Strategic Plan for the 
Evaluation of the Toxicity of Chemicals (US EPA, 2009), in several parts of the document 
and, namely, when it refers to the importance of preserving the original 3D tissue-specific 
heterogeneous microenvironment for improving the predictive potential of in vitro systems 
(“Some toxicities are manifest only when multiple cell types and specific cell-cell interactions are 
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present. Other toxicities may be dependent upon tissue geometry and 3D architecture. Examples 
include signalling between hepatocytes and Kupffer cells, or the many forms of signalling between 
epithelial and mesenchymal cells.”) (US EPA, 2009). 
Ultimately, microgravity-based 3D culture methods could lead to the development of new 
devices, suitable to support, from the clinical point of view, the liver’s essential functions 
(e.g. new-concept "bio-artificial" livers), or lead to the design of innovative protocols for the 
autologous transplantation of normal or engineered hepatocytes, in order to counteract liver 
disorders (e.g. those caused by specific enzymatic defects). 
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These case studies provide much insight into the ongoing evolution of health risk assessments.
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